Letter in Reply
- PMID: 37934553
- DOI: 10.1097/ADM.0000000000001203
Letter in Reply
Conflict of interest statement
DJA receives study materials from Cardiol Therapeutics for a publicly funded clinical trial not related to opioid use disorder. ANH and CW have no conflict of interest to declare.
Comment on
-
Satisfaction With Opioid Agonist Treatment: The Compelling Need for Multidimensional, Patient-centered, Patient-reported Experience Measures.J Addict Med. 2023 Nov-Dec 01;17(6):745. doi: 10.1097/ADM.0000000000001204. Epub 2023 Jul 27. J Addict Med. 2023. PMID: 37934552 No abstract available.
References
-
- Jutras-Aswad D, Le Foll B, Ahamad K, et al. Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial. Am J Psychiatry . 2022;179(10):726–739.
-
- Richardson L, Jaffe K, Socias ME, et al. Research participation in substance use disorder trials: design and methods of a multi-site nested qualitative study [published online October 7, 2022]. doi:10.1177/16094069221131168.
Publication types
LinkOut - more resources
Full Text Sources